2nd UPDATE: Celgene To Buy Gloucester Pharma for At Least $340 Million
08 December 2009 - 5:22AM
Dow Jones News
Celgene Corp. (CELG) agreed to acquire privately held Gloucester
Pharmaceuticals Inc. for $340 million plus milestone payments of up
to $300 million in a deal to bolster its position in blood cancer
treatments.
The deal, Celgene's first major move since buying Pharmion Corp.
for $2.9 billion last year, provides the Summit, N.J., company with
a product that will launch early next year. Celgene, which had 2008
revenue of $2.3 billion, gets most of sales from blood cancer
treatments Revlimid, Thalomid and Vidaza.
Celgene's shares recently traded down 1% to $55.44. Shares of
Allos Therapeutics Inc. (ALTH) fell 14% to $5.70 as it faces future
competition from industy heavyweight Celgene.
The acquisition, expected to close in the first quarter, won't
have a major impact on the balance sheet, which showed $2.8 billion
in cash, cash equivalents, and marketable securities at the end of
September. It will have no impact on earnings in 2010, but it will
add to the bottom-line in 2011, excluding deal-related costs.
Oppenheimer & Co. analyst Brian Abrahams noted that the deal
makes "good strategic sense" for Celgene because of its current
product lineup, although it is not transformative.
Gloucester's Istodax was approved by the Food and Drug
Administration last month for treatment of cutaneous T-cell
lymphoma, or CTCL, a type of non-Hodgkin's lymphoma, in patients
failing prior systemic therapy.
Sanford Bernstein analyst Geoffrey Porges estimates that the
drug could see peak annual sales of $150 million to $240 million in
CTCL, but he warns that sales will build gradually because of slow
disease progress and the long duration of available treatment
regimens.
Istodax is also being studied in peripheral T-cell lymphoma, or
PTCL, with enrollment in a key trial completed early next year and
data coming later in 2010. A Celgene spokesman said the company
could file for approval for PTCL by the end of next year.
The company declined to provide additional details on the future
payments in the deal, except that they will be related to future
U.S. and international regulatory milestones.
The deal structure highlights a trend of drug makers using
structured acquisition agreements with smaller drug developers as a
way to acquire assets, while mitigating failure risk and paying
only for success.
Allos got approval of Folotyn in September for treatment of
PTCL, but now will face formidible competition from
well-established Celgene.
Furthermore, some on Wall Street had hoped that Allos would
strike a partnership or takeover with Celgene, and there is concern
that Folotyn may not be as effective as Istodax.
"There is a feeling that Gloucester might have the better drug
and gotten taken over," said Needham & Co. analyst Mark
Monane.
But he stressed that Celgene's interest in CTCL and PTCL should
provide some validation to Allos investors, because it shows that
the market for such drugs is large.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169;
thomas.gryta@dowjones.com
(Tess Stynes contributed to this report)
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024